Genelux (GNLX) Stock Price, News & Analysis

Company Overview

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents. Preclinical work has also been directed at optimizing dosing regimens and delivery methods to maximize oncolytic activity and immune priming. The company conducts its clinical development programs in collaboration with academic medical centers and research hospitals across North America and Europe, ensuring access to patient populations in regions with high unmet need.

Originally founded as a private research entity, Genelux completed its transition to a publicly traded company in January 2021, listing its common stock on the Nasdaq Global Market under the ticker symbol GNLX. Headquartered in Richmond, Virginia, the company maintains research and administrative operations in the United States, while engaging with contract development and manufacturing organizations (CDMOs) to support viral vector production and scale-up activities.

Genelux’s leadership team is led by Michael P. Sherman, M.D., J.D., who serves as President and Chief Executive Officer. Dr. Sherman brings extensive experience in oncology drug development, regulatory affairs and corporate financing. Under his direction, Genelux is advancing its oncolytic immunotherapy platform with the goal of delivering novel, broadly applicable treatments to patients with refractory solid tumors.

Key Stats

• Today's Range: $2.86 to $2.95
• 50-Day Range: $2.30 to $3.19
• 52-Week Range: $2.29 to $8.53
• Volume: 76,802 shs
• Average Volume: 164,830 shs
• Market Capitalization: $130.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Moderate Buy

Genelux Stock Analysis - MarketRank™

Genelux scored higher than 33% of companies evaluated by MarketBeat, and ranked 717th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Genelux has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Genelux has a consensus price target of $18.00, representing about 516.4% upside from its current price of $2.92.

Amount of Analyst Coverage

Genelux has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Genelux are expected to grow in the coming year, from ($0.80) to ($0.75) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Genelux is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genelux is -3.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Genelux has a P/B Ratio of 5.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.59% of the float of Genelux has been sold short.

Short Interest Ratio / Days to Cover

Genelux has a short interest ratio ("days to cover") of 24.28, which indicates bearish sentiment.

Change versus previous month

Short interest in Genelux has recently increased by 4.22%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genelux does not currently pay a dividend.

Dividend Growth

Genelux does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Genelux this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for GNLX on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Genelux insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $39,828.00 in company stock.

Percentage Held by Insiders

7.50% of the stock of Genelux is held by insiders.

Percentage Held by Institutions

37.33% of the stock of Genelux is held by institutions.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 5/26/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GNLX
• CIK: 1231457
• Web: www.genelux.com
• Phone: 805-267-9889
• Fax: N/A
• Employees: 10
• Year Founded: 2001

Price Target and Rating

• Average Price Target for Genelux: $18.00
• High Price Target: $20.00
• Low Price Target: $16.00
• Potential Upside/Downside: +516.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.85)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$32.15 million
• Net Margins: N/A
• Pretax Margin: -419,762.50%
• Return on Equity: -174.55%
• Return on Assets: -123.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.68
• Quick Ratio: 3.68

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 13,093.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.51 per share
• Price / Book: 5.73

Miscellaneous

• Outstanding Shares: 44,840,000
• Free Float: 41,477,000
• Market Cap: $130.93 million
• Optionable: Not Optionable
• Beta: 0.51